Authors
Georgina V Long, Muhammad A Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo S Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M Mehnert, Patrick A Ott, Reinhard Dummer, Paola Queirolo, Christoffer Gebhardt, Caroline Dutriaux, Carlos Rojas, Yuanbin Chen, Lisa M Tachiki, Ronnie Shapira-Frommer, Oliver Bechter, Ryan J Sullivan, Alexander M M Eggermont, Laureen S Ojalvo, Michelle Brown, Jinchun Zhang, Dmitri O Grebennik, Mizuho Fukunaga-Kalabis, Paolo A Ascierto, Michele Del Vecchio, INTerpath-001 Investigators
Published in
The New England journal of medicine. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
Intismeran autogene (intismeran) is an individualized neoantigen therapy that is designed to induce new T-cell responses and expand preexisting T-cell responses against patient-specific tumor neoantigens, which may potentially improve the efficacy of adjuvant therapy in patients with melanoma.
In this phase 3, double-blind trial, we randomly assigned patients with completely resected stage IIB to IV cutaneous melanoma in a 2:1 ratio to receive intramuscular intismeran (at a dose of 1 mg) or placebo every 3 weeks for nine doses; all the patients received intravenous pembrolizumab (at a dose of 400 mg) every 6 weeks for nine cycles. The primary end point was investigator-determined recurrence-free survival, assessed in a time-to-event analysis. Key secondary end points included investigator-determined distant-metastasis-free survival (assessed in a time-to-event analysis) and safety.
A total of 1137 patients underwent randomization: 757 to the intismeran-pembrolizumab group and 380 to the placebo-pembrolizumab group. The median follow-up was 24.6 months. Recurrence-free survival at 24 months was 82.2% in the intismeran-pembrolizumab group and 70.0% in the placebo-pembrolizumab group (two-sided P<0.001); the piecewise hazard ratio was 0.99 (95% confidence interval [CI], 0.66 to 1.49) before 6 months and 0.42 (95% CI, 0.30 to 0.58) after 6 months. Distant-metastasis-free survival at 24 months was 88.5% with intismeran-pembrolizumab and 80.2% with placebo-pembrolizumab (two-sided P = 0.002); the piecewise hazard ratio was 1.01 (95% CI, 0.58 to 1.79) before 6 months and 0.50 (95% CI, 0.34 to 0.73) after 6 months. Adverse events of grade 3 or higher occurred in 23.6% of the patients in the intismeran-pembrolizumab group and 20.3% of the patients in the placebo-pembrolizumab group. Eight patients (1.1%) in the intismeran-pembrolizumab group died from an adverse event; five of the deaths occurred before intismeran was administered.
Adjuvant therapy with intismeran plus pembrolizumab significantly prolonged recurrence-free survival and distant-metastasis-free survival as compared with pembrolizumab alone in patients with completely resected, high-risk cutaneous melanoma. (Funded by Merck Sharp and Dohme and Moderna; ClinicalTrials.gov number, NCT05933577.).
PMID:
43013837
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 163
- Comments 0